Bruce D. Roth is an American organic and medicinal chemist who trained at Saint Joseph's College, Iowa State University and the University of Rochester, and, at the age of 32, discovered atorvastatin, the statin-class drug sold as Lipitor that would become the largest-selling drug in pharmaceutical history (as of 2003). His honours include being named a 2008 Hero of Chemistry by the American Chemical Society, and being chosen as the Perkin Medal awardee, the highest honour given in the U.S. chemical industry, by the Society of Chemical Industry, American section in 2013.
This section needs expansionwith: sourced DOB, middle name, and other sourced information on early life. You can help by adding to it. (February 2016) |
Roth received his undergraduate degree in chemistry from Saint Joseph's College, Philadelphia, in 1976. [1] He then went to Iowa State University as a doctoral student under George Kraus, receiving his Ph.D. in organic chemistry in 1981. [1] He then spent a year as a Postdoctoral Fellow with A.S. Kende at the University of Rochester.[ citation needed ] [2]
Roth has held a number of positions in his career, from "Scientist" (medicinal chemist) through to vice president-level positions in drug discovery, and his accomplishments in his career include the discovery of the molecule atorvastatin, which would become the drug Lipitor.[ citation needed ]
In 1982, 28-year-old Roth began work as a medicinal chemist for the Parke Davis research area of Warner-Lambert, [2] [3] becoming the chemistry co-chair of the statins effort, with biologist Roger Newton, in 1984. [2] By 1985, he was at Warner-Lambert's Parke-Davis Pharmaceutical Research facility in Ann Arbor, Michigan. [4] He was promoted to Research Associate in 1986, Senior Research Associate in 1988, Section Director in 1990, Director of Atherosclerosis and Exploratory Chemistry in 1992, and Senior Director of Atherosclerosis, Inflammation and Exploratory Chemistry in 1993.[ citation needed ]By the early 1990s he held managerial positions and was no longer doing laboratory work. [5] : 98 In 2000 Warner-Lambert acquired Parke-Davis. He was appointed Vice President of Chemistry just prior to the merger between Warner-Lambert and Pfizer in 2000 and remained in that role as a part of Pfizer Global Research and Development in Ann Arbor, Michigan until 2007. [5] He then joined Genentech in San Francisco, California as Vice President of Discovery Chemistry. [6]
Before atorvastatin, Roth worked to develop a different drug, but Sandoz AG beat his team to a patent.[ clarification needed ] [4] In 1985, while working at Warner-Lambert's Parke-Davis research facility, Roth "identified a molecule" that inhibited HMG CoA reductase, a "key enzyme in the metabolic pathway the body uses to produce cholesterol." [7]
Roth was listed as the inventor of trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one, patented in 1986, and developed into the on-market drug, atorvastatin, which ultimately would be sold as Lipitor, [2] [8] [9] [10] and which would become the largest-selling drug in pharmaceutical history by 2003. [3] Pfizer acquired Warner-Lambert and Lipitor in 2000. [3] [11] [12]
From 1996 until 2007, Roth served as an adjunct professor in the Department of Medicinal Chemistry at the University of Michigan. [13]
For the discovery of atorvastatin, Roth received the 1997 Warner-Lambert Chairman's Distinguished Scientific Achievement Award, [5] the 1999 Inventor of the Year Award from the New York Intellectual Property Law Association,[ citation needed ] the 2003 American Chemical Society Award for Creative Invention, [14] [ better source needed ] the 2003 Gustavus John Esselen Award for Chemistry in the Public Service, [5] the 2005 Iowa State University Distinguished Alumni Award,[ citation needed ] and the 2006 Pfizer Global Research and Development Achievement Award.[ citation needed ][ citation needed ] Roth was named a 2008 Hero of Chemistry by the American Chemical Society. [7] [15] In 2013, he was chosen as the Perkin Medal awardee, the highest honour given in the U.S. chemical industry, by the Society of Chemical Industry, American section, for his innovation in applied chemistry that resulted in the outstanding commercial success of atorvastatin. [1] [ citation needed ]
This section may need to be rewritten to comply with Wikipedia's quality standards, as the format of the citations, while adequate, and academic, is not standard for wikipedia, in particular lacking links and being inconsistent in format with rest of article sources.(February 2016) |
According to the Chemical Heritage Foundation, in "addition to his discovery of atorvastatin, Roth is the inventor or co-inventor of 42 patents and the author or co-author of 48 manuscripts, 35 published abstracts and eight book chapters." [16]
His publications include:
The following are good sources from which further information on the article's subject may be found, that may be of interest to readers and article editors. It includes sources not yet cited, and sources whose content may yet provide further insights into the subject.
Statins, also known as HMG-CoA reductase inhibitors, are a class of lipid-lowering medications that reduce illness and mortality in those who are at high risk of cardiovascular disease. They are the most commonly prescribed cholesterol-lowering drugs.
Atorvastatin, sold under the brand name Lipitor among others, is a statin medication used to prevent cardiovascular disease in those at high risk and to treat abnormal lipid levels. For the prevention of cardiovascular disease, statins are a first-line treatment. It is taken by mouth.
Lovastatin, sold under the brand name Mevacor among others, is a statin medication, to treat high blood cholesterol and reduce the risk of cardiovascular disease. Its use is recommended together with lifestyle changes. It is taken by mouth.
Cerivastatin is a synthetic member of the class of statins used to lower cholesterol and prevent cardiovascular disease. It was marketed by the pharmaceutical company Bayer A.G. in the late 1990s, competing with Pfizer's highly successful atorvastatin (Lipitor). Cerivastatin was voluntarily withdrawn from the market worldwide in 2001, due to reports of fatal rhabdomyolysis.
HMG-CoA reductase is the rate-controlling enzyme of the mevalonate pathway, the metabolic pathway that produces cholesterol and other isoprenoids. HMGCR catalyzes the conversion of HMG-CoA to mevalonic acid, a necessary step in the biosynthesis of cholesterol. Normally in mammalian cells this enzyme is competitively suppressed so that its effect is controlled. This enzyme is the target of the widely available cholesterol-lowering drugs known collectively as the statins, which help treat dyslipidemia.
In stereochemistry, a chiral auxiliary is a stereogenic group or unit that is temporarily incorporated into an organic compound in order to control the stereochemical outcome of the synthesis. The chirality present in the auxiliary can bias the stereoselectivity of one or more subsequent reactions. The auxiliary can then be typically recovered for future use.
Torcetrapib was a drug being developed to treat hypercholesterolemia and prevent cardiovascular disease. Its development was halted in 2006 when phase III studies showed excessive all-cause mortality in the treatment group receiving a combination of atorvastatin (Lipitor) and torcetrapib.
Mevastatin is a hypolipidemic agent that belongs to the statins class.
Pitavastatin is a member of the blood cholesterol lowering medication class of statins.
Akira Endo is a Japanese biochemist whose research into the relationship between fungi and cholesterol biosynthesis led to the development of statin drugs, which are some of the best-selling pharmaceuticals in history.
Lanosterol synthase (EC 5.4.99.7) is an oxidosqualene cyclase (OSC) enzyme that converts (S)-2,3-oxidosqualene to a protosterol cation and finally to lanosterol. Lanosterol is a key four-ringed intermediate in cholesterol biosynthesis. In humans, lanosterol synthase is encoded by the LSS gene.
The discovery of HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) reductase inhibitors, called statins, was a breakthrough in the prevention of hypercholesterolemia and related diseases. Hypercholesterolemia is considered to be one of the major risk factors for atherosclerosis which often leads to cardiovascular, cerebrovascular and peripheral vascular diseases. The statins inhibit cholesterol synthesis in the body and that leads to reduction in blood cholesterol levels, which is thought to reduce the risk of atherosclerosis and diseases caused by it.
Procaterol is an intermediate-acting β2 adrenoreceptor agonist used for the treatment of asthma. It has never been filed for FDA evaluation in the United States, where it is not marketed. The drug is readily oxidized in the presence of moisture and air, making it unsuitable for therapeutic use by inhalation. Pharmaceutical company Parke-Davis/Warner-Lambert researched a stabilizer to prevent oxidation, but an effective one was never developed.
Azacosterol, or azacosterol hydrochloride, also known as 20,25-diazacholesterol, is a cholesterol-lowering drug (hypocholesteremic), which was marketed previously, but has since been discontinued. It is also an avian chemosterilant used to control pest pigeon populations via inducing sterility. The drug is a sterol and derivative of cholesterol in which two carbon atoms have been replaced with nitrogen atoms.
2,4,6-Tribromophenol (TBP) is a brominated derivative of phenol. It is used as a fungicide, as a wood preservative, and an intermediate in the preparation of flame retardants.
Warner–Lambert was an American pharmaceutical company.
Xue-Min Cheng is a medicinal chemist, author and pharmaceutical executive best known as the co-author of The Logic of Chemical Synthesis, which formalized retrosynthesis. The concept for this Elias J. Corey won the 1990 Nobel Prize in Chemistry.
Ezetimibe/rosuvastatin, sold under the brand name Ridutrin among others, is a combination medication used to treat high cholesterol. In some countries it is sold as a kit or a pack containing two distinct pills.
Nirmatrelvir is an antiviral medication developed by Pfizer which acts as an orally active 3C-like protease inhibitor. It is part of a nirmatrelvir/ritonavir combination used to treat COVID-19 and sold under the brand name Paxlovid.
Avasimibe (INN), codenamed CI 1011, is a drug that inhibits sterol O-acyltransferases, enzymes involved in the metabolism and catabolism of cholesterol. It was discovered by Parke-Davis and developed as a possible lipid-lowering agent and treatment for atherosclerosis.
"Subtitle: Lipitor, the cholesterol-lowering drug, has become the bestselling pharmaceutical in history. Here's how Pfizer did it.
Bruce Roth, the inventor of Lipitor, calls the people who make those tough decisions 'drug hunters' and says that it takes between 10 and 15 years to train them. / 'Unfortunately, there are some things that are hard to predict,' said Roth, during a panel discussion this Monday at the American Chemical Society meeting in Philadelphia. 'We still are not very good at understanding which compounds are going to be successful, and which ones will be toxic.'